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INTRODUCTION 
 
Epigenetic modifications, like the methylation of DNA, play an important role in the 
interpretation of genetic information. DNA methylation is a reversible process that 
regulates both gene expression and chromatin organization. There are several 
examples of different DNA methylation patterns in pathologic conditions such as 
imprinting disorders and cancer (1). 
DNA methylation is an epigenetic event in which the addition of a methyl group to 
the fifth carbon position of a cytosine residue (m5C) occurs frequently in CpG 
dinucleotides. This process is closely associated with modifications of chromatin 
structure at gene promoter regions and it plays an important role in regulating gene 
expression (2). In cancer cells, dysregulation DNA methylation may lead to 
hypermethylation of promoter CpG islands, inhibiting the transcriptional initiation of 
controlled genes (3). Methylation of CpG dinucleotides is known to be mediated by 
at least three DNMTs (DNA Methyltransferases), including DNMT3a, DNMT3b, and 
DNMT1. Two of these enzymes, DNMT3a and DNMT3b, are thought to be 
responsible for an initial setup of methylation patterns during the development. 
Because the process of establishing methylation patterns is critical during early 
development, these methyltransferases are highly expressed in embryonic cells but 
are present at lower levels also in adult cells. Instead, DNMT1 is constitutively 
expressed in proliferating cells and it functions as a maintenance enzyme to ensure 
that the methylation patterns are faithfully copied to daughter cells during DNA 
replication (4). 
The possibility to reverse epigenetic modifications has generated considerable 
interest in the development of DNA methyltransferase inhibitors (5). The 
identification and the development of small molecules that block the active sites of 
human DNA methyltransferases represents a new class of epigenetic modifier 
compounds (3). 
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The inhibition of DNMT, especially DNMT1, would block the hypermethylation of 
the new synthesized DNA filament with the result of a reversion of the 
hypermethylation and possibly re-expression of silenced genes (3).  
Generally, drugs used to achieve this aim can be divided into two subgroups: 
nucleoside and non-nucleoside inhibitors (6). The first group consists of Azacitidine 
(5-Azacytidine), Decitabine (5-Aza-2’-deoxycytidine) and Zebularine [1-(b-D-
ribofuranosyl)-2(1H)-pyrimidinone]. They are  established drugs whose function is 
that of suicide inhibitors after their incorporation into DNA. The second group 
contains EGCG [(-)-epigallocatechin-3-gallate], pro-EGCGs (Triolanalog and 
Diolanalog of EGCG) and RG108 [2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-
(1H-indol-3-yl) propanoic acid] that are considered three compounds whose function 
is the inhibition of DNA by interfering with enzyme activity (6).   
It is worth to note that Azacitidine and Decitabine have been approved by the U.S. 
Food and Drug Administration (FDA) for treatment of Mieloid Displastic Syndrome 
(MSD) (7,8). 
Moreover, it had been showed in nude mice that Zebularine can be orally 
administered causing demethylation and reactivation of a silenced and 
hypermethylated p16 gene in human bladder tumor cells (9). One of the major 
problem with the use of inhibitors of DNA methylation is the re-methylation and re-
silencing of genes at the end of the treatment. That makes the clinical application of 
these drugs quite limited. To overcame these limits it could be ideal a drugs that 
could be administered continuously without toxic effects. Interestingly, in (9) 
Zebularine shown high stability in vitro and minimal cytotoxicity also during long 
time treatments. 
These observation suggests possible therapeutic strategies and clinical benefits in the 
continuous application of Zebularine (9). 
Probably, Prader-Willi Syndrome (PWS) represents the best example of genomic 
imprinting diseases in humans (10). At the present time all genetic and epigenetic 
modifications, which cause PWS lead to a loss of expression of the genes that are 
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usually expressed by paternal chromosome on 15q11.2-q13. The absence of the 
paternal copy of these genes or the failure in their expression can cause the total 
absence of these genes expression in affected individuals because genes on maternal 
chromosome are genetically programmed to be silenced by epigenetic factors (11). 
This lack of expression occurs by three primary mechanisms: deletion of a 5–6 Mb 
region from the paternal chromosome 15 (found in 65–75% of affected individuals), 
maternal UniParental Disomy 15 (UPD) (found in 20–30%), and a defect in the 
genomic region that controls the imprinting process called Imprinting Center (IC) (1–
5%) (11).  
The major clinical manifestations of PWS include hypotonia with weak suck and 
poor feeding in infancy leading to failure-to-thrive, and later development of 
hyperfagia. Other clinical features include developmental delay, cognitive disability, 
and behavioral problems: stubborness, obsessive-compulsive behaviors, and skin 
picking. The major endocrine manifestation of PWS are: high level of hormone 
ghrelin, deficiency of growth hormone (GH), central adrenal insufficiency, 
hipogonadism, hypothyroidism, diabetes and altered glucose metabolism (12). 
 
 
AIMS OF THE RESEARCH 
 
The vast majority of Prader-Willi patients have a hypermethilated state of SNURF-
SNRPN gene promoter, that seems to be the causative agent of the syndrome. We 
have hypothesize that DNA methiltransferases might be used to demethylate the 
promoter and reactivate the genes controlled by it.  
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RESULTS 
 
To test this hypothesis, lymphoblastoid cell line (DMI) derived from EBV-
immortalized lymphocytes from a Prader-Willi patient with defect of imprinting were 
used. 
We tested their time and dose effect on DMI cells as demethylating agents. 
Specifically, to test their ability to reactivate the expression of genes under the 
control of the Imprinting Center, we tested the expression of SNURF-SNRPN gene. In 
detailes, we explored the effect of DNMT inhibitors on SNURF-SNRPN gene 
expression through end-point duplex PCR and subsequently by TaqMan Real Time 
assay. Our study demonstrates that silenced SNURF-SNRPN gene can be reactivated 
by DNMT inhibitors treatments. 
Moreover we investigated the global demethylation effect of DNMT inhibitors noting 
an overall low demethylating effect. The expression of DMNT1 gene, evaluated by 
RT-PCR, was not different between controls and treated samples at different drugs 
concentrations and different time-points. 
These results show that the use of those drugs may be useful to reverse aberrant DNA 
methylation, restoring critical gene functions, and thereby might be used to treat 
imprinting disorders such as Prader-Willi Syndrome. 
These effects occur in a context of minimal cellular toxicity, low global genomic 
hypomethylation, while maintaining the expression of the DNMT1. 
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